Plasma Myeloperoxidase Levels in Patients With Coronary Artery Disease

Evaluation of the Association Between Myeloperoxidase Levels and Cardiovascular Risk Factors in Patients With Coronary Artery Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01239979

Enrollment

150

Registered

2010-11-15

Start date

2009-01-31

Completion date

2010-11-30

Last updated

2010-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

coronary artery disease

Brief summary

The investigators sought to assess whether plasma myeloperoxidase (MPO) levels differ among patients with stable and unstable CAD patients and control subjects, and correlate with inflammatory and clinical risk factors such as ox-LDL, NO,leptin, adiponectin, sPLA2, Lp-PLA2, homocysteine and 3-nitrotyrosine in the patients.

Detailed description

Elevation of the leukocyte enzyme myeloperoxidase (MPO) in stable coronary artery disease (CAD) patients in contrast to unstable CAD patients is controversial and its relationship with some inflammatory and noninflammatory markers such as oxidized LDL (ox-LDL) and nitric oxide (NO) in the CAD patients has not been evaluated yet. Evaluation of these relationships is the aim of the study.Also the relationships between MPO and some other inflammatory biomarker such as leptin, adiponectin, sPLA2, Lp-PLA2, homocysteine and 3-nitrotyrosine are examined. This study includes 50 stable CAD, 50 unstable CAD patients and 50 controls. Plasma MPO, ox-LDL, leptin, adiponectin, sPLA2 levels are determined using enzyme immunoassay.Homocysteine and 3-nitrotyrosine are measured using HPLC-fluorescence method. Plasma total NO and other risk factors such as lipid profile, hypertension, smoking, diabetes mellitus and familial history of CAD are also determined in the patients. Results are statistically analysed and the association between all markers are assessed.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

35 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Stable and unstable patients with angiographically documented coronary artery disease. * Control subjects without angiographically documented coronary artery disease. All subjects

Exclusion criteria

* Patients with recent (with in 6 month) myocardial infarction or cardiovascular events, * surgery (with in 3 month), * cancer and * infective or inflammatory diseases were not included in the study.

Design outcomes

Primary

Measure	Time frame
Plasma myeloperoxidase levels	3 month

Secondary

Measure	Time frame
Clinical risk factors	3 month

Countries

Iran

Outcome results